Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New trial tests shorter radiation for head and neck cancer that has returned

NCT ID NCT03164460

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This phase II trial compares two types of radiation for people whose head and neck cancer has come back and cannot be removed with surgery. One method delivers high-dose radiation in fewer sessions, while the other uses standard daily doses over several weeks. The study aims to see which approach causes fewer severe side effects and better controls the cancer. It includes 68 participants with small tumors who have already had radiation before.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiation therapy (stereotactic body radiation therapy or intensity-modulated radiation/proton therapy)
What this could lead to
If successful, this trial could show that a shorter, more precise radiation treatment is safer and works as well as standard radiation for people with recurrent head and neck cancer.
What could go wrong
This is a small, early-phase trial that is currently suspended. It only includes people with small tumors who cannot have surgery, so results may not apply to everyone. Radiation to previously treated areas carries risks of severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

68 people

The number who actually took part.

Started

May 2017

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with histologically documented recurrent head and neck cancer, or second primary head and neck cancer, AND who have previously received radiation (at least 30 Gy) for head and neck cancer * Not eligible for surgery for recurrence or poor surgical candidate * Gross disease apparent on imaging (magnetic resonance imaging \[MRI\] or computed tomography \[CT\]) * 1-3 sites of recurrence (\< 60 cc per site, total volume \< 100 cc) * Eastern Cooperative Oncology Group (ECOG) = 0, 1, or 2 * Negative pregnancy test for women of child bearing potential Exclusion Criteria: * Patients who are pregnant or breast feeding * Clinically significant uncontrolled major cardiac, respiratory, renal, hepatic, gastrointestinal or hematologic disease but not limited to: * a) Symptomatic congestive heart failure, unstable angina, or cardiac dysrhythmia not controlled by pacer device * b) No myocardial infarction within 3 months of registration * Widely metastatic disease (oligometastatic disease acceptable)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent head and neck cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.